Bridgefront Capital, LLC Tricida, Inc. Transaction History

Bridgefront Capital, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 12, 2021	SELL	$3.95 - $5.41 $45,270 - $62,004	-11,461 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$4.52 - $7.8 $36,657 - $63,258	-8,110 Reduced 41.44%	11,461 $61,000
Q4 2020 Feb 12, 2021	BUY	$4.37 - $9.46 $85,525 - $185,141	19,571 New	19,571 $138,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Bridgefront Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgefront Capital, LLC with notifications on news.